Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative Diseases

Abstract

Echinacoside (ECH) is a natural phenylethanoid glycoside (PhG) in Cistanche tubulosa. A large number of studies have shown that ECH has very promising potential in the inhibition of neurodegenerative disease progression. Experimental studies strongly suggest that ECH exhibits a variety of beneficial effects associated with in neuronal function, including protecting mitochondrial function, anti-oxidative stress, anti-inflammatory, anti-endoplasmic reticulum stress (ERS), regulating autophagy and so on. The aim of this paper is to provide an extensive and actual summarization of ECH and its neuroprotective efficacy in prevention and treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and so on, based on published data from both in vivo and in vitro studies. There is a growing evidence that ECH may serve as an efficacious and safe substance in the future to counteract neurodegenerative disease.

1 Introduction

With the increase in population aging, neurodegenerative diseases are the most prevalent and fastest growing disorders of the elderly worldwide, which are endangering human health and cause a heavy financial burden on society (Erkkinen et al., 2018). The number of the dementia elderly is expected to increase to 130 million by 2050, and the annual socio-economic cost per patient is US$19,144.36, the global cost is estimated to reach US$9.12 trillion by 2050 (Jia et al., 2018; Hansson, 2021). Neurodegenerative diseases mainly include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), vascular dementia (VD), and so on (Gitler et al., 2017). Neuronal damage, mitochondrial dysfunction, oxidative stress and neuroinflammation are their common pathogenesis feature. The neurodegenerative diseases are mainly manifested as memory and cognitive impairment, and abnormal movement in clinic (Enogieru et al., 2018). Up to now, the therapeutic strategy for neurodegenerative diseases mainly focuses on improving symptoms. Therefore, it is urgent to explore and develop novel drugs with therapeutic potential directed at the pathogenesis of neurodegenerative disease.

Echinacoside (ECH, Figure 1) is a phenylethanoid glycoside (PhG), and was first extracted from the rhizome of Echinacea angustifolia DC. It is not only one of the key effective components of Echinacea (Jiang and Tu, 2009; Zhu et al., 2013; Li et al., 2018), but also abundant in other natural plants, such as Scrophulariae Radix, Rehmanniae Radix, Cistanches Herba, etc. Among them, Cistanche tubulosa contains the highest content of ECH reaching about 30% (w/w) (Tian XY et al., 2021). The molecular formula of ECH is C₃₅H₄₆O₂₀ (Figure 1) and its chemical structure is composed of a sugar group, a phenylpropenyl group, and a phenylethanol group (Wu et al., 2020). Recently, ECH has shown a variety of important pharmacological activities, such as anti-inflammatory, protection of mitochondrial function, anti-oxidation, anti-neurotoxicity, anti-endoplasmic reticulum stress (ERS), anti-apoptosis, and neuroprotective effect (Wang et al., 2015; Chen et al., 2018; Ma et al., 2019; Wei et al., 2019; Wu et al., 2020). In addition, the metabolites of ECH C6-C3 and C6-C2 may have certain neuroprotective activities, which can directly supplement the neurotransmitter defects (Song et al., 2019). This review presented current and innovative results concerning the pharmacology and the efficacy of ECH in the treatment of neurodegenerative diseases, focusing on its mechanism of action in AD, PD, VD, and ALS, etc.

FIGURE 1

2 Alzheimer’s Disease

AD is an irreversible and progressive chronic central neurodegenerative disease. It is the most common type of dementia and is becoming a major challenge to global health and social care (Alzheimer’s Association, 2020). Patients with AD usually suffer from significant memory impairment, language difficulties, decreased executive and visuospatial functions, and other degrees of cognitive impairment, as well as personality and behavior changes (Hansson, 2021). The pathogenesis mainly includes oxidative stress, mitochondrial abnormalities, neuroinflammation, abnormal accumulation of extracellular Amyloid-β (Aβ) plaques, and so on (Lane et al., 2018; Magalingam et al., 2018). AD involves multiple pathogeneses. The current treatment strategy for a single pathway has been proved to be insufficient. Recent evidences indicate that ECH has very extensive neuropharmacological activities. It may be a potential natural active ingredient with broad-spectrum and multiple target effects in the treatment of AD.

2.1 The Production and Toxicity of Amyloid-β

Excessive accumulation of Aβ oligomers and soluble aggregates outside the central nerve cells of the brain is one of the important causes of AD (Imbimbo and Watling, 2019). Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) is the key rate-limiting enzyme for amyloid precursor protein (APP) processing to produce Aβ, which can catalyze the initial cleavage of APP and produce Aβ. Dai et al. confirm that ECH affects Protein kinase-like endoplasmic reticulum kinase (PERK), inhibits the PERK/eIF2α pathway to reduce ERS, and regulates F-actin remodeling to reduce the excessive accumulation of Aβ and the expression of BACE1 protein by using immunohistochemistry, Aβ plaque load quantification, Aβ ELISA, RNA isolation, quantitative PCR, Western blot analysis, BACE1 activity assay and Transmission Electron Microscopy in APPswe/PS1dE9 (2 × Tg-AD) mice (Dai et al., 2020). In the hen egg-white lysozyme (HEWL) model system, Zhang et al. used spectroscopic analyses, electron microscopy, cell viability assay, and hemolysis assay to find that ECH can inhibit the conversion of HEWL in a dose-dependent manner, antagonize amyloidosis, destroy the structure of fibrils, and convert amyloid fibrils into amorphous aggregates (Zhang et al., 2015). In addition, in Amyloid β peptide 1-42 (Aβ 1-42)-treated SH-SY5Y cells, Shiao et al. found that ECH inhibited Aβ_1-42 oligomerization, restored the cell viability that was reduced by Aβ_1-42, and reduced acetylcholinesterase activity, which in turn reverses cortical cholinergic dysfunction caused by Aβ_1-42 in Aβ_1-42-infused rat (Shiao et al., 2017). Wu et al. used the AD rats induced by injecting Aβ_1-42 and found ECH can ameliorate the cognitive deficits, decrease amyloid deposition and reverse cholinergic and hippocampal dopaminergic dysfunction caused by Aβ_1-42 (Wu et al., 2014).

2.2 Oxidative Stress

The central nervous system requires high energy, so it is one of the organs that is vulnerable to hypoxia (Wilson et al., 2009). The presence of oxidative damage in neuronal lipids and proteins is an important feature of AD. The binding of redox-active metal ions to Aβ and mitochondrial dysfunction can catalyze the production of reactive oxygen species (ROS) (Cheignon et al., 2018). Studies have shown that ECH has significant antioxidant and free radical scavenging properties. Nuclear factor-erythroid 2-related factor 2 (Nrf2) is one of the most important transcription factors in oxidative stress. ECH significantly decreased the Kelch-like ECH-associated protein-1 (Keap1) protein expression along with the substantial nuclear accumulation of Nrf2 in hippocampus. ECH further elevated the expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1) and γ-glutamyl cysteine Synthetase (γ-GCS). Then, Nrf2 promotes the transcription of key antioxidative enzymes, such as superoxide dismutase (SOD) and phase II detoxifying genes (such as NQO1), and regulates the Keap1-Nrf2-ARE pathway to depress oxidative stress and mitochondrial dysfunction (Zheng et al., 2019). In the Caenorhabditis elegans, ECH suppressed oxidative stress via the DR pathway and the insulin/IGF signaling (IIS) pathway, which triggers the nuclear localization of DAF-16. Then DAF-16 regulates target genes which participate in lifespan regulation and stress resistance. ECH also increased its two downstream targets, namely superoxide dismutase (sod-3) and small heat shock protein 16.2 (hsp-16.2) which involved in oxidative damage (Mukhopadhyay et al., 2006; Chen et al., 2018). Furthermore, ECH could ameliorate the pathology of AD through decreasing the formation of ROS and the accumulation of intracellular free Ca²⁺, and improving the mitochondrial membrane integrity (Kuang et al., 2009).

2.3 Neuroprotection

Glutamate is the main excitatory neurotransmitter. Excessive release of glutamate and excessive excitement of N-methyl-D-aspartate receptor (NMDAR) can cause depolarization of nerve cell membranes and cause a large amount of Ca²⁺ influx, which is an important cause of neuronal degeneration and death (Cobley et al., 2018). According to the research results of Lu and others, in the rat cerebral cortex, ECH can reduce voltage-dependent Ca²⁺ influx and inhibit protein kinase C activity (Lu et al., 2016). Shiao et al. infuse Aβ_1-42 into the brain cistern by an osmotic pump and found that ECH can inhibit AChE activity, reverse cortical cholinergic neuron dysfunction caused by Aβ deposition, and improve cognitive dysfunction caused by Aβ_1-42. Achieve protection of nerves from toxic effects (Shiao et al., 2017).

2.4 Apoptosis

ECH can inhibit the release of cytochrome c (Cyt c) and the activation of caspase-3 through the extracellular signal-regulated kinase (ERK) pathway in vitro (Zhu et al., 2013). The members of the Bcl-2 family-like Bax and Bcl-2 have participated in apoptosis induced by the accumulation of ROS through the mitochondrial apoptotic pathway (Deng et al., 2004; Soane et al., 2008). ECH prevents a H₂O₂-induced increase of the Bax/Bcl-2 ratio to depress apoptosis in rat pheochromocytoma cell line (PC12 cells) (Kuang et al., 2009).

3 Parkinson’s Disease

PD is a chronic progressive neurodegenerative disease. Its clinical symptoms mainly include resting tremor, bradykinesia, muscle rigidity, and postural and gait disorders. The typical neuropathological features of PD are the degeneration of dopaminergic neurons located in the substantial nigra pars compacta (SNpc) of the midbrain and the formation of Lewy bodies, and α-synuclein and ubiquitin are the main components of Lewy bodies (Dunnett and Björklund, 1999). Recent studies have shown that the loss of dopaminergic terminals in the striatum, rather than the loss of SNpc neurons, is crucial for the occurrence of motor symptoms. With the aging of the global population, the prevalence of PD is expected to double in the next 20 years (Simon et al., 2020).

3.1 Neuroinflammation

ECH inhibits the activation of microglia and astrocytes in 6-hydroxydopamine (6-OHDA) subacute PD model mice and promotes the nerves of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), high vanillic acid (HVA), norepinephrine (NE), and serotonin (5-HT) in the striatum and extracellular fluid of the hippocampus. Secretion of nutritional factors (Chen et al., 2007), and finally, the apoptosis of DA neurons is reduced, and the pathological state of PD is improved. It is also reported in the literature that ECH can prevent the level of DA, DOPAC, and HVA in the right striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model mice from decreasing (Zhang et al., 2021a). At the same time, inhibiting the reduction of striatal fibers, DA and DA transporters can improve gait disorders. In vitro experiments show that ECH can improve 6-OHDA-induced PC12 cell model cell viability, significantly enhance redox activity and mitochondrial membrane potential, reduce ROS production, and inhibit mitochondrial-mediated apoptosis (Chen et al., 2019). MPTP is converted into 1-methyl-4-phenylpyridinium (MPP⁺) by monoamine oxidase B in glial cell species. MPP⁺ produces neurotoxicity by generating ROS in DA neuron mitochondria (Ahmed et al., 2017). MPP⁺ is now widely used to induce damage in SH-SY5Y cell line to mimic the pathogenesis of PD. After ECH administration, it has been shown to attenuate DA neuron damages. Zhang et al. used proteomics to detect pro-inflammatory cytokines and found that seven cytokines including c5/c5a, interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2), and interleukin-4 (IL-4) were down-regulated by down-regulating p38 mitogen Pro-activated protein kinase (p38MAPK) and nuclear factor-kappa B (NF-κB) p52 (Zhang J et al., 2017; Liang et al., 2019) or regulate the activation of ROS/ATF3/CHOP pathway participate in the inhibition of inflammation in dopaminergic neurons in the midbrain the occurrence of the reaction, thereby inhibiting the occurrence of apoptosis, has a neuroprotective effect (Zhao et al., 2016). The excessive activation of microglia is closely related to neurotoxicity and participates in the main pathological development of PD. The inflammatory response mediated by activated microglia is the main component of the pathological process of PD. In the ECH group of MPTP model mice, the specific marker Iba-1 of microglia in the midbrain decreased, and ECH treatment inhibited the small activation of glial cells which improves inflammation in the brain (Ho, 2019). There are also reports in the literature that ECH improves the neuropathological state of PD mice through neuroprotective cell survival and inhibiting activated microglia-mediated NLRP3/CASP-1/IL-1β inflammation signals (Gao et al., 2020). In summary, ECH can depress the neuroinflammation that involved in the pathological progress of PD by multiple ways.

3.2 Apoptosis

Bcl-2 is the coding product of the Bcl-2 proto-oncogene and is an apoptosis-inhibiting protein. It promotes cell survival by inhibiting the permeability of the outer mitochondrial membrane, regulates the release of mitochondrial apoptotic factors, participates in the regulation of apoptosis, and promotes cells’ survive (Liu et al., 2019). In MPTP subacute PD model mice, ECH inhibits the release of mitochondrial Cyt c and caspase-8 and the lysis of caspase-3 by reducing the ratio of Bax/Bcl-2 in dopamine neurons in the substantia nigra and plays a role of inhibiting apoptosis.

3.3 Autophagy

In the pathological process of PD, the disorder of autophagy regulation will eventually lead to the accumulation of misfolded proteins and the damage of organelles. The autophagy-lysosome pathway can not only degrade proteins that cannot be degraded by the ubiquitin-proteasome pathway, but also degrade α-synuclein (Webb et al., 2003). Autophagy is the main pathway for the degradation of intracellular aggregates, and mechanistic target of rapamycin (mTOR) kinase is the key regulatory site for autophagy (Glick et al., 2010). By regulating the autophagy-lysosome pathway and increasing the degradation of autophagy and α-synuclein, the addition of ECH has significant advantages in improving the clinical efficacy and clinical symptoms of PD. Zhang et al. used MPTP to create a subacute PD mouse model. ECH can significantly improve the neurobehavior of PD mice by upregulating the survival signal p-AKT/AKT The expression of mTOR inhibits the expression of mTOR, thereby promoting the clearance of α-synuclein and the degradation of the autophagy substrate P62, exerting a neuroprotective effect (Zhang et al., 2021b). Sirtuins are nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylases that play an important role in neuronal development and aging, which also have neuroprotective effects in PD models in vivo and in vitro (Donmez and Outeiro, 2013). It has been proved that sirtuin 1 (SIRT1) promotes the transcription of HSP70 (heat shock protein) and other molecular chaperones by deacetylating heat shock factor 1, and is an effective regulator of autophagy. Experiments have shown that ECH binds to SIRT1, and the binding product activates forkhead box subgroup O1 (FoxO1) to cause autophagy gene transcription. And translation, promote the autophagic degradation of α-synuclein, which can reverse the damage of dopaminergic neurons (Chen et al., 2019).

3.4 Nourishment of Nerves

The neurotrophic factor is a protein for the growth and survival of neurons, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF). It can promote the growth and development of nerves and axons. The increased incidence of neuronal apoptosis and the decreased protective effect of neurotrophic factors caused by various pathological factors are the basis of dopaminergic neuron degeneration (Barker et al., 2020). GDNF has the strongest neurotrophic factor that protects and promotes the repairment of dopaminergic neurons. ECH improved the viability of MPP⁺-treated cell in vivo, and increased the expression of tyrosine hydroxylase (TH), GDNF, GDNF family receptor α (GFRα1) and Ret in cells of substantia nigra (SN) of MPTP-induced PD mouse model (Xu et al., 2016).

3.5 Endoplasmic Reticulum Stress

Seipin/BSCL2 has been identified as the pathogenic gene for Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) and induces the most severe form of lipodystrophy, characterized by an almost complete absence of adipose tissue and associated metabolic disorders. Seipin is a global membrane protein of the endoplasmic reticulum (ER) that plays a key role in adipogenesis, lipid droplet homogenization, and cellular triglyceride lipolysis (Wang et al., 2018). Seipin accumulation strongly impaired adipocyte isotropy and leads to lipodystrophy, showing potential neural involvement. Chronic ERS leads to the accumulation of α-synuclein, and unfolded proteins in ER further leads to neuronal death (Licker et al., 2014). ECH attenuates the accumulation of Seipin (BSCL2) in 6-OHDA-induced rat models by promoting its ubiquitination and degradation, thereby reducing the activation of ERS related pathways (Zhang Y et al., 2017).

3.6 Mitochondrial Dysfunction

Mitochondria are key organelles for adenosine 5′-triphosphate (ATP) production through oxidative phosphorylation (OXPHOS), which is necessary for normal cellular functions. OXPHOS generates electron donor NADH and flavin adenine dinucleotide (FADH₂) through electron transport chain (ETC) transmission to produce ATP (Filograna et al., 2021). The spare respiratory capacity (SRC) that mitochondria reserve under normal physiological conditions is critical for cell survival under stress when energy needs increase or oxygen depletion occurs. Complex I is the main entry point of ETC and is the site that mainly produces lesions or injuries. MMP induces the mouse model of PD by inhibiting complex I, suggesting that complex I may be the core of PD pathogenesis (Iverson, 2013), and it is another entry point for ETC and is used to reduce equivalents. There is evidence that complex II is a key regulator of neuroprotection, and complex II is a major source of SRC. In the human neuroblastoma SH-SY5Y cell line, ECH selectively attenuated cell damage and reversed complex I by increasing the activity of complex II to ameliorate the mitochondrial respiratory disorder and bioenergy shortage (Ma et al., 2019). ECH could also increase the mitochondrial membrane potential, and restore the mitochondrial energy supply in 6-OHDA-treated PC12 cells.

4 Other Neurodegenerative Disease

Compared with the study of the mechanism that ECH is used to treat AD and PD, the mechanism of ECH’s potential therapeutic effect on ALS, VD, and other diseases research is still very few. ALS is a type of motor neuron disease characterized by the degeneration of more than motor neurons and lower motor neurons. Yang Tian’s research team found that 10 μM ECH promoted the expression of glutamate transporter 1 (GLT1) in astrocytes, and found that ECH can significantly improve neuron survival and synapse loss treated with superoxide dismutase 1 (SOD1) astrocyte conditioned medium. Western blot and MTS were used. As well as immunohistochemistry and confocal imaging, this clarifies to a certain extent that ECH has a potential therapeutic effect on ALS (Tian Y et al., 2021). However, the molecular mechanism of 10 μM ECH promoting GLT1 expression needs more exploration. VD is a disease of severe cognitive impairment often caused by cerebrovascular diseases such as hemorrhagic or ischemic stroke. In previous studies, ECH has been found to have a certain promoting effect on the restoration of ACh and choline levels in the hippocampus and striatum of VD model rats, and it can also significantly increase the activity of AChE. The recovery of the cholinergic nervous system of VD rats has a promoting effect, but the specific molecular mechanism remains to be further discovered (Liu et al., 2013). And Xu Liu et al. also showed that ECH can up-regulate the expression of GDNF in the hippocampus by regulating the level of mitochondrial oxidation, thereby reducing the ischemic damage of VD rat neurons and improving learning and memory function (Liu et al., 2017).

5 Conclusion and Future Directions

Neurodegenerative diseases have caused a tremendous burden to patient’s family and society worldwide. Up to now, therapeutic drugs remain very scarce. Natural active ingredients may be one of the promising drug discovery strategies for AD treatment. As a natural PhG, ECH has been confirmed to be have multiple neuroprotective effects such as anti-oxidative stress, anti-apoptosis, anti-neuroinflammation, inhibit the accumulation of toxic protein and regulate autophagy and ERS (Figure 2,3). All of this implied that ECH possess broad-spectrum and multiple target neuropharmacological effects, suggesting ECH may be a potential candidate compounds to develop therapeutic drug for treating neurodegenerative diseases with multi-target collaborative intervention. Here, we enumerate the neuroprotective effects of ECH against neurodegenerative diseases based on current reports and results (Table 1).

FIGURE 2

FIGURE 3

References

• 1

  AhmedH.AbushoukA. I.GabrM.NegidaA.Abdel-DaimM. M. (2017). Parkinson's Disease and Pesticides: A Meta-Analysis of Disease Connection and Genetic Alterations. Biomed. Pharmacother.90, 638–649. 10.1016/j.biopha.2017.03.100

  • CrossRef
  • Google Scholar

• 2

  Alzheimer's Association (2020). 2020 Alzheimer's Disease Facts and Figures. Alzheimers Dement (16), 391–460. 10.1002/alz.12068

  • CrossRef
  • Google Scholar

• 3

  BarkerR. A.BjörklundA.GashD. M.WhoneA.Van LaarA.KordowerJ. H.et al (2020). GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J. Parkinsons Dis.10 (3), 875–891. 10.3233/jpd-202004

  • CrossRef
  • Google Scholar

• 4

  CheignonC.TomasM.Bonnefont-RousselotD.FallerP.HureauC.CollinF. (2018). Oxidative Stress and the Amyloid Beta Peptide in Alzheimer's Disease. Redox Biol.14, 450–464. 10.1016/j.redox.2017.10.014

  • CrossRef
  • Google Scholar

• 5

  ChenH.JingF. C.LiC. L.TuP. F.ZhengQ. S.WangZ. H. (2007). Echinacoside Prevents the Striatal Extracellular Levels of Monoamine Neurotransmitters from Diminution in 6-hydroxydopamine Lesion Rats. J. Ethnopharmacol.114 (3), 285–289. 10.1016/j.jep.2007.07.035

  • CrossRef
  • Google Scholar

• 6

  ChenW.LinH. R.WeiC. M.LuoX. H.SunM. L.YangZ. Z.et al (2018). Echinacoside, a Phenylethanoid Glycoside from Cistanche Deserticola, Extends Lifespan of Caenorhabditis elegans and Protects from Aβ-Induced Toxicity. Biogerontology19 (1), 47–65. 10.1007/s10522-017-9738-0

  • CrossRef
  • Google Scholar

• 7

  ChenC.XiaB.TangL.WuW.TangJ.LiangY.et al (2019). Echinacoside Protects against MPTP/MPP+-induced Neurotoxicity via Regulating Autophagy Pathway Mediated by Sirt1. Metab. Brain Dis.34 (1), 203–212. 10.1007/s11011-018-0330-3

  • CrossRef
  • Google Scholar

• 8

  CobleyJ. N.FiorelloM. L.BaileyD. M. (2018). 13 Reasons Why the Brain Is Susceptible to Oxidative Stress. Redox Biol.15, 490–503. 10.1016/j.redox.2018.01.008

  • CrossRef
  • Google Scholar

• 9

  DaiY.HanG.XuS.YuanY.ZhaoC.MaT. (2020). Echinacoside Suppresses Amyloidogenesis and Modulates F-Actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer's Disease. Front. Cel Dev. Biol.8, 593659. 10.3389/fcell.2020.593659

  • CrossRef
  • Google Scholar

• 10

  DengM.ZhaoJ. Y.TuP. F.JiangY.LiZ. B.WangY. H. (2004). Echinacoside Rescues the SHSY5Y Neuronal Cells from TNFalpha-Induced Apoptosis. Eur. J. Pharmacol.505 (1-3), 11–18. 10.1016/j.ejphar.2004.09.059

  • CrossRef
  • Google Scholar

• 11

  DonmezG.OuteiroT. F. (2013). SIRT1 and SIRT2: Emerging Targets in Neurodegeneration. EMBO Mol. Med.5 (3), 344–352. 10.1002/emmm.201302451

  • CrossRef
  • Google Scholar

• 12

  DunnettS. B.BjörklundA. (1999). Prospects for New Restorative and Neuroprotective Treatments in Parkinson's Disease. Nature399 (6738 Suppl. l), A32–A39. 10.1038/399a032

  • CrossRef
  • Google Scholar

• 13

  EnogieruA. B.HaylettW.HissD. C.BardienS.EkpoO. E. (2018). Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. Oxid. Med. Cel Longev.2018, 6241017. 10.1155/2018/6241017

  • CrossRef
  • Google Scholar

• 14

  ErkkinenM. G.KimM. O.GeschwindM. D. (2018). Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol.10 (4), a033118. 10.1101/cshperspect.a033118

  • CrossRef
  • Google Scholar

• 15

  FilogranaR.MennuniM.AlsinaD.LarssonN. G. (2021). Mitochondrial DNA Copy Number in Human Disease: the More the Better?FEBS Lett.595 (8), 976–1002. 10.1002/1873-3468.14021

  • CrossRef
  • Google Scholar

• 16

  GaoM. R.WangM.JiaY. Y.TianD. D.LiuA.WangW. J.et al (2020). Echinacoside Protects Dopaminergic Neurons by Inhibiting NLRP3/Caspase-1/IL-1β Signaling Pathway in MPTP-Induced Parkinson's Disease Model. Brain Res. Bull.164, 55–64. 10.1016/j.brainresbull.2020.08.015

  • CrossRef
  • Google Scholar

• 17

  GitlerA. D.DhillonP.ShorterJ. (2017). Neurodegenerative Disease: Models, Mechanisms, and a new hope. Dis. Model. Mech.10 (5), 499–502. 10.1242/dmm.030205

  • CrossRef
  • Google Scholar

• 18

  GlickD.BarthS.MacleodK. F. (2010). Autophagy: Cellular and Molecular Mechanisms. J. Pathol.221 (1), 3–12. 10.1002/path.2697

  • CrossRef
  • Google Scholar

• 19

  HanssonO. (2021). Biomarkers for Neurodegenerative Diseases. Nat. Med.27 (6), 954–963. 10.1038/s41591-021-01382-x

  • CrossRef
  • Google Scholar

• 20

  HoM. S. (2019). Microglia in Parkinson's Disease. Adv. Exp. Med. Biol.1175, 335–353. 10.1007/978-981-13-9913-8_13

  • CrossRef
  • Google Scholar

• 21

  ImbimboB. P.WatlingM. (2019). Investigational BACE Inhibitors for the Treatment of Alzheimer's Disease. Expert Opin. Investig. Drugs28 (11), 967–975. 10.1080/13543784.2019.1683160

  • CrossRef
  • Google Scholar

• 22

  IversonT. M. (2013). Catalytic Mechanisms of Complex II Enzymes: a Structural Perspective. Biochim. Biophys. Acta1827 (5), 648–657. 10.1016/j.bbabio.2012.09.008

  • CrossRef
  • Google Scholar

• 23

  JiaJ.WeiC.ChenS.LiF.TangY.QinW.et al (2018). The Cost of Alzheimer's Disease in China and Re-estimation of Costs Worldwide. Alzheimers Dement14 (4), 483–491. 10.1016/j.jalz.2017.12.006

  • CrossRef
  • Google Scholar

• 24

  JiangY.TuP. F. (2009). Analysis of Chemical Constituents in Cistanche Species. J. Chromatogr. A.1216 (11), 1970–1979. 10.1016/j.chroma.2008.07.031

  • CrossRef
  • Google Scholar

• 25

  KuangR.SunY.YuanW.LeiL.ZhengX. (2009). Protective Effects of Echinacoside, One of the Phenylethanoid Glycosides, on H(2)O(2)-induced Cytotoxicity in PC12 Cells. Planta Med.75 (14), 1499–1504. 10.1055/s-0029-1185806

  • CrossRef
  • Google Scholar

• 26

  LaneC. A.HardyJ.SchottJ. M. (2018). Alzheimer's Disease. Eur. J. Neurol.25 (1), 59–70. 10.1111/ene.13439

  • CrossRef
  • Google Scholar

• 27

  LiL.WanG.HanB.ZhangZ. (2018). Echinacoside Alleviated LPS-Induced Cell Apoptosis and Inflammation in Rat Intestine Epithelial Cells by Inhibiting the mTOR/STAT3 Pathway. Biomed. Pharmacother.104, 622–628. 10.1016/j.biopha.2018.05.072

  • CrossRef
  • Google Scholar

• 28

  LiangY.ChenC.XiaB.WuW.TangJ.ChenQ.et al (2019). Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson's Disease. Biomed. Res. Int.2019, 4379639. 10.1155/2019/4379639

  • CrossRef
  • Google Scholar

• 29

  LickerV.TurckN.KövariE.BurkhardtK.CôteM.Surini-DemiriM.et al (2014). Proteomic Analysis of Human Substantia Nigra Identifies Novel Candidates Involved in Parkinson's Disease Pathogenesis. Proteomics14 (6), 784–794. 10.1002/pmic.201300342

  • CrossRef
  • Google Scholar

• 30

  LiuC. L.ChenH.JiangY.TuP. F.ZhongM.MaJ. Y.et al (2013). Effects of Echinacoside on Extracellular Acetylcholine and Choline Levels of hippocampus and Striatum of Cerebral Ischemia Rats. Yao Xue Xue Bao48 (5), 790–793.

  • Google Scholar

• 31

  LiuX.LuoQ. H.ZhouJ.WanX. L.ZhangH. Y.WanZ. G.et al (2017). Effects of Echinacoside on GDNF Expression and Mitochondrial Oxidative Stress Levels in Vascular Dementia Rats. Int. J. Clin. Exp. Med.10 (5), 7752–7759.

  • Google Scholar

• 32

  LiuJ.LiuW.YangH. (2019). Balancing Apoptosis and Autophagy for Parkinson's Disease Therapy: Targeting BCL-2. ACS Chem. Neurosci.10 (2), 792–802. 10.1021/acschemneuro.8b00356

  • CrossRef
  • Google Scholar

• 33

  LuC. W.LinT. Y.HuangS. K.WangS. J. (2016). Echinacoside Inhibits Glutamate Release by Suppressing Voltage-dependent Ca(2+) Entry and Protein Kinase C in Rat Cerebrocortical Nerve Terminals. Int. J. Mol. Sci.17 (7), 1006. 10.3390/ijms17071006

  • CrossRef
  • Google Scholar

• 34

  MaH.LiuY.TangL.DingH.BaoX.SongF.et al (2019). Echinacoside Selectively Rescues Complex I Inhibition-Induced Mitochondrial Respiratory Impairment via Enhancing Complex II Activity. Neurochem. Int.125, 136–143. 10.1016/j.neuint.2019.02.012

  • CrossRef
  • Google Scholar

• 35

  MagalingamK. B.RadhakrishnanA.PingN. S.HaleagraharaN. (2018). Current Concepts of Neurodegenerative Mechanisms in Alzheimer's Disease. Biomed. Res. Int.2018, 3740461. 10.1155/2018/3740461

  • CrossRef
  • Google Scholar

• 36

  MukhopadhyayA.OhS. W.TissenbaumH. A. (2006). Worming Pathways to and from DAF-16/FOXO. Exp. Gerontol.41 (10), 928–934. 10.1016/j.exger.2006.05.020

  • CrossRef
  • Google Scholar

• 37

  ShiaoY. J.SuM. H.LinH. C.WuC. R. (2017). Echinacoside Ameliorates the Memory Impairment and Cholinergic Deficit Induced by Amyloid Beta Peptides via the Inhibition of Amyloid Deposition and Toxicology. Food Funct.8 (6), 2283–2294. 10.1039/c7fo00267j

  • CrossRef
  • Google Scholar

• 38

  SimonD. K.TannerC. M.BrundinP. (2020). Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin. Geriatr. Med.36 (1), 1–12. 10.1016/j.cger.2019.08.002

  • CrossRef
  • Google Scholar

• 39

  SoaneL.SiegelZ. T.SchuhR. A.FiskumG. (2008). Postnatal Developmental Regulation of Bcl-2 Family Proteins in Brain Mitochondria. J. Neurosci. Res.86 (6), 1267–1276. 10.1002/jnr.21584

  • CrossRef
  • Google Scholar

• 40

  SongQ.LiJ.HuoH.CaoY.WangY.SongY.et al (2019). Retention Time and Optimal Collision Energy Advance Structural Annotation Relied on LC-MS/MS: An Application in Metabolite Identification of an Antidementia Agent Namely Echinacoside. Anal. Chem.91 (23), 15040–15048. 10.1021/acs.analchem.9b03720

  • CrossRef
  • Google Scholar

• 41

  TianX. Y.LiM. X.LinT.QiuY.ZhuY. T.LiX. L.et al (2021). A Review on the Structure and Pharmacological Activity of Phenylethanoid Glycosides. Eur. J. Med. Chem.209, 112563. 10.1016/j.ejmech.2020.112563

  • CrossRef
  • Google Scholar

• 42

  Tian YY.JinS.PromesV.LiuX.ZhangY. (2021). Astragaloside IV and Echinacoside Benefit Neuronal Properties via Direct Effects and through Upregulation of SOD1 Astrocyte Function In Vitro. Naunyn Schmiedebergs Arch. Pharmacol.394 (5), 1019–1029. 10.1007/s00210-020-02022-w

  • CrossRef
  • Google Scholar

• 43

  WangX.ZhangJ.LuL.ZhouL. (2015). The Longevity Effect of Echinacoside in Caenorhabditis elegans Mediated through Daf-16. Biosci. Biotechnol. Biochem.79 (10), 1676–1683. 10.1080/09168451.2015.1046364

  • CrossRef
  • Google Scholar

• 44

  WangL.HongJ.WuY.LiuG.YuW.ChenL. (2018). Seipin Deficiency in Mice Causes Loss of Dopaminergic Neurons via Aggregation and Phosphorylation of α-synuclein and Neuroinflammation. Cell Death Dis.9 (5), 440. 10.1038/s41419-018-0471-7

  • CrossRef
  • Google Scholar

• 45

  WebbJ. L.RavikumarB.AtkinsJ.SkepperJ. N.RubinszteinD. C. (2003). Alpha-Synuclein Is Degraded by Both Autophagy and the Proteasome. J. Biol. Chem.278 (27), 25009–25013. 10.1074/jbc.M300227200

  • CrossRef
  • Google Scholar

• 46

  WeiW.LanX. B.LiuN.YangJ. M.DuJ.MaL.et al (2019). Echinacoside Alleviates Hypoxic-Ischemic Brain Injury in Neonatal Rat by Enhancing Antioxidant Capacity and Inhibiting Apoptosis. Neurochem. Res.44 (7), 1582–1592. 10.1007/s11064-019-02782-9

  • CrossRef
  • Google Scholar

• 47

  WilsonM. H.NewmanS.ImrayC. H. (2009). The Cerebral Effects of Ascent to High Altitudes. Lancet Neurol.8 (2), 175–191. 10.1016/s1474-4422(09)70014-6

  • CrossRef
  • Google Scholar

• 48

  WuC. R.LinH. C.SuM. H. (2014). Reversal by Aqueous Extracts of Cistanche Tubulosa from Behavioral Deficits in Alzheimer's Disease-like Rat Model: Relevance for Amyloid Deposition and central Neurotransmitter Function. BMC Complement. Altern. Med.14, 202. 10.1186/1472-6882-14-202

  • CrossRef
  • Google Scholar

• 49

  WuL.GeorgievM. I.CaoH.NaharL.El-SeediH. R.SarkerS. D.et al (2020). Therapeutic Potential of Phenylethanoid Glycosides: A Systematic Review. Med. Res. Rev.40 (6), 2605–2649. 10.1002/med.21717

  • CrossRef
  • Google Scholar

• 50

  XuQ.FanW.YeS. F.CongY. B.QinW.ChenS. Y.et al (2016). Cistanche Tubulosa Protects Dopaminergic Neurons through Regulation of Apoptosis and Glial Cell-Derived Neurotrophic Factor: In Vivo and In Vitro. Front. Aging Neurosci.8, 295. 10.3389/fnagi.2016.00295

  • CrossRef
  • Google Scholar

• 51

  ZhangD.LiH.WangJ. B. (2015). Echinacoside Inhibits Amyloid Fibrillization of HEWL and Protects against Aβ-Induced Neurotoxicity. Int. J. Biol. Macromol.72, 243–253. 10.1016/j.ijbiomac.2014.08.034

  • CrossRef
  • Google Scholar

• 52

  ZhangZ. N.HuiZ.ChenC.LiangY.TangL. L.WangS. L.et al (2021a). Neuroprotective Effects and Related Mechanisms of Echinacoside in MPTP-Induced PD Mice. Neuropsychiatr. Dis. Treat.17, 1779–1792. 10.2147/ndt.S299685

  • CrossRef
  • Google Scholar

• 53

  ZhangZ. N.HuiZ.ChenC.LiangY.TangL. L.WangS. L.et al (2021b). Mechanism of Autophagy Regulation in MPTP-Induced PD Mice via the mTOR Signaling Pathway by Echinacoside. Neuropsychiatr. Dis. Treat.17, 1397–1411. 10.2147/ndt.S299810

  • CrossRef
  • Google Scholar

• 54

  Zhang JJ.ZhangZ.XiangJ.CaiM.YuZ.LiX.et al (2017). Neuroprotective Effects of Echinacoside on Regulating the Stress-Active p38MAPK and NF-κB P52 Signals in the Mice Model of Parkinson's Disease. Neurochem. Res.42 (4), 975–985. 10.1007/s11064-016-2130-7

  • CrossRef
  • Google Scholar

• 55

  Zhang YY.LongH.ZhouF.ZhuW.RuanJ.ZhaoY.et al (2017). Echinacoside's Nigrostriatal Dopaminergic protection against 6-OHDA-Induced Endoplasmic Reticulum Stress through Reducing the Accumulation of Seipin. J. Cel Mol. Med.21 (12), 3761–3775. 10.1111/jcmm.13285

  • CrossRef
  • Google Scholar

• 56

  ZhaoQ.YangX.CaiD.YeL.HouY.ZhangL.et al (2016). Echinacoside Protects against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation. Neurosci. Bull.32 (4), 349–362. 10.1007/s12264-016-0047-4

  • CrossRef
  • Google Scholar

• 57

  ZhengH.SuY.SunY.TangT.ZhangD.HeX.et al (2019). Echinacoside Alleviates Hypobaric Hypoxia-Induced Memory Impairment in C57 Mice. Phytother Res.33 (4), 1150–1160. 10.1002/ptr.6310

  • CrossRef
  • Google Scholar

• 58

  ZhuM.LuC.LiW. (2013). Transient Exposure to Echinacoside Is Sufficient to Activate Trk Signaling and Protect Neuronal Cells from Rotenone. J. Neurochem.124 (4), 571–580. 10.1111/jnc.12103

  • CrossRef
  • Google Scholar